Janna Krueger

8.8k total citations · 1 hit paper
14 papers, 6.5k citations indexed

About

Janna Krueger is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Janna Krueger has authored 14 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Immunology. Recurrent topics in Janna Krueger's work include Cancer Immunotherapy and Biomarkers (7 papers), Immunotherapy and Immune Responses (5 papers) and Zebrafish Biomedical Research Applications (4 papers). Janna Krueger is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Immunotherapy and Immune Responses (5 papers) and Zebrafish Biomedical Research Applications (4 papers). Janna Krueger collaborates with scholars based in Canada, Germany and United Kingdom. Janna Krueger's co-authors include Ferdinand le Noble, Sebastian D. Mackowiak, Sebastian Memczak, Christine Kocks, Francesca Torti, Marvin Jens, Lea H. Gregersen, Alexander Loewer, Mathias Munschauer and Markus Landthaler and has published in prestigious journals such as Nature, Nature Communications and The Journal of Immunology.

In The Last Decade

Janna Krueger

14 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circular RNAs are a large class of animal RNAs with regulatory potency

2013 6.2k citations Sebastian Memczak, Marvin Jens et al. Nature profile →

Peers

Countries citing papers authored by Janna Krueger

Since Specialization

Citations

This map shows the geographic impact of Janna Krueger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janna Krueger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janna Krueger more than expected).

Fields of papers citing papers by Janna Krueger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janna Krueger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janna Krueger. The network helps show where Janna Krueger may publish in the future.

Co-authorship network of co-authors of Janna Krueger

This figure shows the co-authorship network connecting the top 25 collaborators of Janna Krueger. A scholar is included among the top collaborators of Janna Krueger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janna Krueger. Janna Krueger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Clinical significance of glycogen synthase kinase 3 (GSK-3) expression and tumor budding grade in colorectal cancer: Implications for targeted therapy 2023 ·Biomedicine & Pharmacotherapy ·Silvia Guil‐Luna, (unknown), (unknown), (unknown), Alejandra Pera, (unknown), (unknown), Maria Victoria García‐Ortiz, (unknown), (unknown), Janna Krueger, Francisco Fernández, Juan de la Haba-Rodríguez, Auxiliadora Gómez‐España, Enrique Aranda, Christopher E. Rudd, Antonio Rodríguez‐Ariza	7
2	Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy 2021 ·PLoS ONE ·Janna Krueger, (unknown), (unknown), Mark E. Issa, Bruno Larrivée, Richard Kremer, (unknown), Christopher E. Rudd	13
3	CD28 and glycogen synthase kinase-3 (GSK-3) inhibitor combination therapy generates tumor infiltrating T-cells (TILs) with a reversal of markers for T-cell exhaustion 2020 ·The Journal of Immunology ·(unknown), Janna Krueger, Christopher E. Rudd	2
4	Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications 2019 ·Seminars in Immunology ·Janna Krueger, Christopher E. Rudd, Alison Taylor	17
5	Glycogen synthase kinase 3 (GSK-3) synergizes with immune-checkpoint blockade (ICB) to overcome tumor resistance due to unique tumor infiltrating T-cell subsets as revealed by mass cytometry (CyTOF) 2019 ·The Journal of Immunology ·Janna Krueger, Alison Taylor, Vinicius N. Motta, John Stagg, Ian R. Watson, Christopher E. Rudd	1
6	Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors 2018 ·Molecular Cancer Therapeutics ·Elizabeth A. Kuczynski, Janna Krueger, Annabelle Chow, Ping Xu, Shan Man, Yogi Sundaravadanam, Jessica K. Miller, Paul M. Krzyzanowski, Robert S. Kerbel	20
7	Glycogen synthase kinase-3 (GSK-3) inactivation compensates for the lack of CD28 in the priming of CD8+ cytotoxic T-cells: Implications for anti-PD-1 immunotherapy 2018 ·The Journal of Immunology ·Christopher E. Rudd, Janna Krueger, Alison Taylor	1
8	Neuronal sFlt1 and Vegfaa determine venous sprouting and spinal cord vascularization 2017 ·Nature Communications ·(unknown), (unknown), Masanari Takamiya, Yuya Hayashi, Uwe Strähle, Koji Ando, Naoki Mochizuki, Andreas van Impel, Stefan Schulte‐Merker, Janna Krueger, Laëtitia Préau, Ferdinand le Noble	56
9	CD28 family of receptors inter-connect in the regulation of T-cells 2017 ·PubMed ·Janna Krueger, (unknown), Sadiye Amcaoglu Rieder, Christopher E. Rudd	5
10	Circular RNAs are a large class of animal RNAs with regulatory potency breakdown → 2013 ·Nature ·Sebastian Memczak, Marvin Jens, (unknown), Francesca Torti, Janna Krueger, Agnieszka Rybak‐Wolf, (unknown), Sebastian D. Mackowiak, Lea H. Gregersen, Mathias Munschauer, Alexander Loewer, Ulrike Ziebold, Markus Landthaler, Christine Kocks, Ferdinand le Noble, Nikolaus Rajewsky	6168
11	The role of blood flow and microRNAs in blood vessel development 2011 ·The International Journal of Developmental Biology ·Dong Liu, Janna Krueger, Ferdinand le Noble	16
12	Flt1 acts as a negative regulator of tip cell formation and branching morphogenesis in the zebrafish embryo 2011 ·Journal of Cell Science ·Janna Krueger, Dong Liu, (unknown), (unknown), Yu Shi, Christian Klein, Arndt F. Siekmann, Stefan Schulte‐Merker, Melissa Cudmore, Asif Ahmed, Ferdinand le Noble	2
13	Flt1 acts as a negative regulator of tip cell formation and branching morphogenesis in the zebrafish embryo 2011 ·Development ·Janna Krueger, Dong Liu, (unknown), (unknown), Yu Shi, Christian Klein, Arndt F. Siekmann, Stefan Schulte‐Merker, Melissa Cudmore, Asif Ahmed, Ferdinand le Noble	132
14	Neuron navigator 3a regulates liver organogenesis during zebrafish embryogenesis 2011 ·Development ·Christian Klein, (unknown), Janna Krueger, (unknown), Joep Brinkmann, Dong Liu, Justus Veerkamp, (unknown), Salim Abdelilah‐Seyfried, Ferdinand le Noble	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact